Overview

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Status:
NOT_YET_RECRUITING

Trial end date:
2026-04-30

Target enrollment:

Participant gender:

Summary

This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed with high-dose Furmonertinib plus bevacizumab for EGFR-mutant non-small cell lung cancer patients with leptomeningeal metastases after resistance to third-generation EGFR-TKIs.

Phase:

PHASE2

Details

Lead Sponsor:

Hunan Province Tumor Hospital

Treatments:

aflutinib
Bevacizumab